mi-viri Arcturus Therapeutics ( NASDAQ: ARCT ) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic fibrosis. The stock rallied last week in reaction to early data from the study posted ahead of a presentation at the European Cystic Fibrosis Conference on Friday. The readout represented 36 study participants, including four adults with cystic fibrosis who received ARCT-032 as part of a Phase 1b trial.
Following the event, based on eight-day interim data from the Phase 1b trial, Arcturus ( ARCT ) said ARCT-032, on average, led to a nearly 6% relative change in FEV1 (forced expiratory volume in 1 second), a metric used to measure lung function in cystic fibrosis. The company noted that patients and healthy individuals in the early-stage trials didn’t develop severe adverse events linked to the drug. It added that ARCT-032, an inhaled messenger-RNA-based therapy, was generally safe and well tolerated.
More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus gains after early-stage data for cystic fibrosis therapy Arcturus Therapeutics Q1 Earnings Preview Seeking Alpha’s Quant Rating on Arcturus Therapeutics.